TABLE 3.
Estimated number of new cancer cases by age in Afghanistan male population, 2020.
| Cancer | Total | 0–14 | 15–39 | 40–44 | 45–49 | 50–54 | 55–59 | 60–64 | 65–69 | 75+ | Crude Rate | ASR (World) | Cum. risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stomach | 1342 (13.10%) | 2 | 70 | 38 | 82 | 139 | 202 | 230 | 220 | 359 | 6.7 | 16.2 | 4.21 |
| Lung | 1070 (10.44%) | 6 | 48 | 55 | 95 | 133 | 168 | 181 | 163 | 221 | 5.4 | 12.3 | 2.71 |
| Lip, oral cavity | 618 (6.03%) | 6 | 107 | 56 | 63 | 71 | 75 | 73 | 63 | 104 | 3.1 | 6.4 | 1.44 |
| Leukemia | 606 (5.91%) | 244 | 208 | 27 | 25 | 23 | 22 | 18 | 15 | 24 | 3 | 3.5 | 0.48 |
| Colorectum | 594 (5.80%) | 105 | 40 | 49 | 58 | 72 | 80 | 76 | 114 | 3 | 6.3 | – | |
| Brain, central nervous system | 588 (5.74%) | 92 | 205 | 54 | 54 | 50 | 45 | 35 | 25 | 28 | 2.9 | 4.3 | 0.57 |
| Esophagus | 569 (5.55%) | 24 | 17 | 35 | 53 | 72 | 85 | 88 | 195 | 2.8 | 7.3 | 2.44 | |
| Liver | 553 (5.40%) | 18 | 60 | 25 | 41 | 56 | 71 | 79 | 76 | 127 | 2.8 | 6.2 | 1.58 |
| Prostate | 450 (4.39%) | 8 | 5 | 6 | 10 | 40 | 81 | 112 | 188 | 2.3 | 6.1 | 1.85 | |
| Kidney | 386 (3.77%) | 41 | 55 | 34 | 41 | 46 | 46 | 41 | 33 | 49 | 1.9 | 3.7 | 0.73 |
| Bladder | 377 (3.68%) | 31 | 16 | 26 | 37 | 51 | 62 | 62 | 92 | 1.9 | 4.4 | 1.07 | |
| Non‐Hodgkin lymphoma | 348 (3.40%) | 51 | 114 | 27 | 27 | 28 | 27 | 25 | 21 | 28 | 1.7 | 2.7 | 0.44 |
| Pancreas | 222 (2.17%) | 1 | 20 | 10 | 15 | 23 | 30 | 35 | 35 | 53 | 1.1 | 2.6 | 0.65 |
| Larynx | 204 (1.99%) | 11 | 12 | 19 | 26 | 34 | 35 | 29 | 38 | 1.0 | 2.3 | 0.47 | |
| Testis | 182 (1.78%) | 19 | 117 | 17 | 11 | 7 | 5 | 3 | 2 | 1 | 0.91 | 1.0 | 0.09 |
| Hodgkin lymphoma | 138 (1.35%) | 40 | 60 | 8 | 6 | 6 | 6 | 4 | 4 | 4 | 0.69 | 0.79 | 0.08 |
| Oropharynx | 104 (1.02%) | 1 | 7 | 4 | 8 | 11 | 14 | 17 | 15 | 27 | 0.52 | 1.2 | 0.26 |
| Hypopharynx | 98 (0.96%) | 6 | 4 | 3 | 12 | 17 | 20 | 16 | 20 | 0.49 | 1.2 | 0.27 | |
| Nasopharynx | 85 (0.83%) | 8 | 31 | 7 | 7 | 6 | 7 | 7 | 6 | 6 | 0.43 | 0.66 | 0.1 |
| Multiple myeloma | 69 (0.67%) | 27 | 5 | 3 | 5 | 5 | 6 | 7 | 11 | 0.35 | 0.67 | 0.19 | |
| Thyroid | 65 (0.63%) | 2 | 17 | 5 | 9 | 10 | 8 | 6 | 5 | 3 | 0.33 | 0.56 | 0.07 |
| Melanoma of skin | 65 (0.63%) | 1 | 17 | 7 | 3 | 3 | 4 | 6 | 9 | 15 | 0.33 | 0.67 | 0.19 |
| Gallbladder | 49 (0.48%) | 5 | 1 | 4 | 5 | 7 | 8 | 7 | 12 | 0.25 | 0.58 | 0.16 | |
| Salivary glands | 34 (0.33%) | 9 | 2 | 2 | 3 | 4 | 4 | 4 | 6 | 0.17 | 0.33 | 0.06 | |
| Kaposi sarcoma | 18 (0.18%) | 5 | 5 | 1 | 2 | 3 | 2 | 0.09 | 0.16 | 0.03 | |||
| Penis | 11 (0.11%) | 1 | 1 | 2 | 2 | 1 | 1 | 3 | 0.06 | 0.12 | 0.02 | ||
| Mesothelioma | 11 (0.11%) | 4 | 1 | 2 | 2 | 1 | 1 | 0.06 | 0.09 | 0.01 | |||
| All cancers excluding non‐melanoma skin cancer | 10 246 (100.00%) | 722 (7.05%) | 1676 (16.36%) | 585 (5.71%) | 757 (7.39%) | 954 (9.31%) | 1175 (11.47%) | 1275 (12.44%) | 1208 (11.79%) | 1894 (18.49%) | 51.3 | 104.5 | 21.45 |
Note: The incidence, prevalence proportions (prop.), crude rates, and ASR were reported per 100 000 people.